Jennifer Doudna

The Nobel-winning co-discoverer of the CRISPR genome-editing system, Doudna had a busy 2021. Her startup Mammoth Biosciences, which raised $195 million in September and achieved a “unicorn” valuation above $1 billion, developed a CRISPR-based diagnostic test for Covid-19 that received an emergency use authorization from the FDA in early 2022. Meanwhile, the Innovative Genomics Institute, which she founded at Berkeley, joined a study testing whether CRISPR can be used to correct the mutated gene that causes sickle cell disease.

From STAT:

• Two female CRISPR scientists make history, winning Nobel Prize in chemistry for genome-editing discovery
• Jennifer Doudna and Marty Chavez on where CRISPR meets Wall Street
• The CRISPR story: How a basic research discovery changed science and led to a Nobel